Voronoi, Inc. (KOSDAQ:310210)

Market Cap	3.36T +100.7%
Revenue (ttm)	7.51B
Net Income	-50.60B
EPS	-2,800.06
Shares Out	18.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,372
Open	182,700
Previous Close	181,000
Day's Range	169,500 - 195,000
52-Week Range	91,000 - 375,500
Beta	1.27
Analysts	Strong Buy
Price Target	350,000.00 (+87.67%)
Earnings Date	Aug 14, 2026

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 140
• Stock Exchange: KOSDAQ
• Ticker Symbol: 310210

Analyst Summary

According to 3 analysts, the average rating for 310210 stock is "Strong Buy." The 12-month stock price target is ₩350,000, which is an increase of 87.67% from the latest price.

Price Target

₩350,000

(87.67% upside)

Analyst Consensus: Strong Buy